It is likely that the proportion of enrolled patients with concurrent obesity and/or diabetes (ranged from 11% to 39%) who can have more pronounced activation of the NLRP3 inflammasome was too low to allow detection of mortality benefits (Table 1).21, 22. Here, NLRP3 is linked to obesity due to melanocortin 4 receptor deficiency.